- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03398122
Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma (HCC)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
HCC The is a common malignancy in the world, especially in China. Advanced HCC treatment is difficult and the prognosis is poor, which is still a great challenge and threat to the medical profession. The advent of the molecular targeted drug, Sola, has made the treatment dilemma of advanced HCC a breakthrough, but the efficacy and economic health ratio is far from satisfactory. After Sola, many new molecular targeted drugs were studied, but failed.
Although multiple treatment options, but for HCC Patient-recommended treatment programs require systematic treatment and surgery, TACE , local ablation and radiotherapy and other multidisciplinary means of combination, the selection of appropriate patients, appropriate means and timing to achieve individualized treatment.
1. Aptinib Union TACE can be generated through embolization and angiogenesis by the dual target of vascular suppression;2. TACE induces hypoxia, leading to an increase in the number of hypoxia-inducing factors that increases VEGF and PDGFR , while VEGF the and PDGFR may be important factors that induce tumor recurrence by stimulating tumor angiogenesis.
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Haipeng Yu, MD
- Número de teléfono: 13352070835
- Correo electrónico: jieruke@yahoo.com.cn
Copia de seguridad de contactos de estudio
- Nombre: Zhi Guo, MD
- Número de teléfono: 18622221211
- Correo electrónico: cjr.guozhi@vip.163.com
Ubicaciones de estudio
-
-
Tianjin
-
Tianjin, Tianjin, Porcelana, 300060
- Reclutamiento
- Tianjin Medical University Cancer Hospital
-
Contacto:
- Haipeng Yu, MD
- Número de teléfono: 13352070835
- Correo electrónico: jieruke@yahoo.com.cn
-
Sub-Investigador:
- Wenge Xing, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age: 18-70 years old;
- initial treatment diagnosed by histopathological or cytological examination BCLC Staging B/C Hepatocellular carcinoma of the liver ( HCC ) and at least one of the largest tumors in measurable lesions ≤15cm ;
- Child-pugh liver function Rating: A level, B level;
- BCLC Staging as B / C period;
before join in the group 1 weeks ECOG PS Rating: 0-1 score; estimated Lifetime ≥12 Week; Lab metrics meet the following criteria: ( 1 ) Blood routine check:
- HB≥90 g/L;
- ANC≥1.5x109/L;
- PLT≥60x109/L; ( 2 ) Biochemical Examination:
- ALB≥29 g/L;
- ALT and AST<2.5*ULN;
- TBIL ≤ 2*ULN;
- Cr ≤ 1.5*ULN;
- women of childbearing age must be pregnancy tests before join in the group in 7 days;
- Participants volunteered to join this study should sign informed consent, with good compliance and follow-up.
Exclusion Criteria:
- Central hepatic artery / hepatic venous fistula in patients with hepatocellular carcinoma, diffuse liver cancer patients, with large vascular invasion of liver cancer patients (including portal vein tumor thrombus);
- hepatobiliary cell carcinoma and mixed cell carcinoma are known; previous ( 5 year) or at the same time suffering from other incurable malignancies, except for the cured basal cell carcinoma of the skin and cervical carcinoma in situ;
- clinically symptomatic ascites that requires therapeutic celiac puncture or drainage with high blood pressure and cannot be reduced to normal range by anti hypertensive medications (systolic pressure > 140 mmHg , diastolic pressure >90 mmHg );
- Suffering Ⅱ above-level myocardial ischemia or myocardial infarction, control of poor arrhythmia (including QTC inter-phase male ≥450 ms , female ≥470 ms );
- Follow NYHA Standard Ⅲ ~ Ⅳ grade heart insufficiency or heart color Doppler ultrasonography: LVEF (left ventricular ejection fraction) < 50% ;
- There are various factors affecting oral medication (e.g.inability to swallow, chronic diarrhea and intestinal obstruction, which significantly affect drug use and absorption);
- previous within 6 months there is a history of gastrointestinal bleeding or a clear tendency to gastrointestinal bleeding, such as: bleeding risk of esophageal varices, local active ulcer lesions, fecal occult blood ≥ ( ++ ) not in group; fecal occult blood (+ ), requiring gastroscopy;
- before participating in this study There were abdominal fistula, gastrointestinal perforation or celiac abscess in the day;
- Coagulation dysfunction ( INR > 1.5 or prothrombin time ( PT ) > ULN+4 seconds), with bleeding tendencies or undergoing thrombolysis or anticoagulant therapy;
- patients who have undergone central nervous system metastasis or known brain metastases;
- patients with objective evidence of the history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, and severe lung impairment;
- urine proteins are routinely shown ≥++ or confirmed 24 hour urine protein ration > 1.0 g ;
- before participating in the study 7 days use strong-effect in CYP3A4 inhibitor therapy, or prior to participating in the study 12 days use the strong-effect in CYP3A4 inducer Therapy;
- pregnant or lactating women who are not willing or unable to take effective contraceptive measures;
- A history of mental illness, or psychotropic substance abuse;
- Union HIV infected patients;
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Apatinib combined with TACE
patients received Aptinib, 250 mg daily after TACE treatment, for 4-6 weeks
|
epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
Otros nombres:
a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor
Otros nombres:
|
Comparador de placebos: chemoemtranscatherer arterial bolization
epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
|
a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
PFS
Periodo de tiempo: one and a half year
|
progression free survival
|
one and a half year
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
OS
Periodo de tiempo: one and a half year
|
overall survival
|
one and a half year
|
TTP
Periodo de tiempo: one and a half year
|
time to progression
|
one and a half year
|
DCR
Periodo de tiempo: one and a half year
|
disease control rate
|
one and a half year
|
ORR
Periodo de tiempo: one and a half year
|
objective response rate
|
one and a half year
|
QOL
Periodo de tiempo: one and a half year
|
number of participants with treatment-related adverse events as assessed by EORTC QLQ-C30
|
one and a half year
|
Colaboradores e Investigadores
Investigadores
- Silla de estudio: Zhi Guo, MD, Tianjin Medical University Cancer Institute & Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias por tipo histológico
- Neoplasias
- Neoplasias por sitio
- Adenocarcinoma
- Neoplasias Glandulares y Epiteliales
- Neoplasias del Sistema Digestivo
- Enfermedades del HIGADO
- Neoplasias Hepaticas
- Carcinoma
- Carcinoma Hepatocelular
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Inhibidores de la proteína quinasa
- Apatinib
Otros números de identificación del estudio
- Ahead-HBH001
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre TACE
-
Beijing Tsinghua Chang Gung HospitalDesconocidoCarcinoma hepatocelular (CHC) con trombo tumoral en la vena porta tipo III (PVTT)Porcelana
-
Beijing Tsinghua Chang Gung HospitalDesconocidoCarcinoma hepatocelular enorme (HCC) (≥10 cm)Porcelana
-
Shanghai Zhongshan HospitalReclutamientoCarcinoma hepatocelular | DonafenibPorcelana
-
Sun Yat-sen UniversityDesconocidoCarcinoma hepatocelular | Cáncer de hígadoPorcelana
-
Sun Yat-sen UniversityDesconocidoCarcinoma hepatocelular | Cáncer de hígadoPorcelana
-
Kindai UniversityDesconocidoCarcinoma Hepatocelular | Carcinoma hepatocelular | Neoplasia Hepática | Carcinoma hepatocelular irresecableJapón
-
Ivy Life Sciences, Co., LtdTri-Service General HospitalDesconocidoCáncer de hígado | Carcinoma hepatocelularTaiwán
-
Ain Shams UniversityTerminado
-
Zhongda HospitalReclutamiento
-
Fudan UniversityDesconocidoCarcinoma hepatocelularPorcelana